Belinostat (PXD-101) that bears a more rigid alkenyl hydroxamic acid is the third HDAC inhibitor to be approved by US FDA in 2014 [69] for the treatment of PTCL. Here, HDAC9 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.